Arthritis news. Anytime. Anywhere.

Call for patient organization input on apremilast for moderate to severe plaque psoriasis

Megaphone GraphicCall for patient organization input on apremilast (Otezla®) for moderate to severe plaque psoriasis

Do you have moderate to severe plaque psoriasis or care for someone who does? If so, we need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for apremilast (Otezla®) for the treatment of moderate to severe plaque psoriasis. Apremilast is an oral, small-molecule compound, taken as two tablets twice a day. In phase II and III clinical trials it has been shown to be effective and well tolerated for treating plaque psoriasis. The medication works by inhibiting the action of phosphodiesterase-4 (PDE4). PDE4 is an enzyme found in immune cells.

Continue reading

Do you know someone who deserves an award?

The Qualman-Davies Arthritis Consumer Community Leadership Award

Award TrophyDo you know a person with arthritis who has, or is, providing leadership in the community and deserves recognition for their valuable volunteer work? We encourage you to help us celebrate their contributions by nominating them for the Qualman-Davies Arthritis Consumer Community Leadership Award.

The Qualman-Davies Arthritis Consumer Community Leadership Award was created in 2014 to recognize one person’s contributions to helping all Canadians living with the disease to be heard in decision-making processes that affect millions. That’s what Ann Qualman and Jim Davies did as early pioneers in arthritis advocacy in Canada. Their tireless and selfless efforts helped millions of Canadians.

Nomination process:

To submit a nomination, please follow the four steps listed below.

  1. Obtain the prospective nominee’s consent to be nominated prior to submitting this form.
  2. Click here to for the nomination form . If you create a separate nomination document, please use the headings provided on the Nomination Form PDF for ease of review by the award adjudication committee.
  3. Provide the completed nomination form to the nominee for their review for accuracy and obtain their signature on the document.
  4. Submit the form to info@jointhealth.org.

The application deadline is October 10, 2014. Each submission will be reviewed by the award adjudication committee and scored on a points system. The successful nominee and their nominator will be provided notification of the award selection by the adjudication committee chair by October 17, 2014. The award will be bestowed in person at the Arthritis Alliance of Canada’s Annual Conference Gala, this year taking place on October 31, 2014 in Toronto, Ontario.

Good News for Arthritis Research

Government of BC awards ARC $3 million for arthritis research. Left to right: Ron McKerrow, ARC Board Chair; Minister Terry Lake, Minister of Health; Dr. John Esdaile, Scientific Director ARC; Minister Teresa Wat, MLA Richmond Centre; Linda Reid, Speaker of the House & MLA, Richmond East. Sign they are standing behind says, "Supporting Arthritis Research and Prevention".

Government of BC awards ARC $3 million for arthritis research. Left to right: Ron McKerrow, ARC Board Chair; Minister Terry Lake, Minister of Health; Dr. John Esdaile, Scientific Director ARC; Minister Teresa Wat, MLA Richmond Centre; Linda Reid, Speaker of the House & MLA, Richmond East

The Government of BC donates $3 million for arthritis research.

The Government of British Columbia’s Health Minister, Terry Lake, made an incredible announcement during a press conference on Tuesday afternoon: $3 million dollars will go to the Arthritis Research Centre of Canada (ARC) to help further developments in arthritis prevention, diagnosis, and treatment.

As a disease that encompasses more than 100 forms, arthritis is the leading cause of disability. For this reason, its impact on the Canadian economy is estimated to be $33 billion each year in healthcare costs and lost productivity. During the announcement, Minister Lake said “With this investment, our government aims to help the Arthritis Research Centre continue to improve the lives of British Columbians living with arthritis, as well as reduce the burden arthritis puts on our healthcare system.” Continue reading

Arthritis in the News

Arthritis is a hot topic in the news this Arthritis Awareness Month.

Cheryl Koehn, president of Arthritis Consumer Experts and Dr. Kam Shojania of the Arthritis Research Centre of Canada (ARC), were recently interviewed on Breakfast Television – Vancouver. Press play on the video above to watch the interview.

Shortly following that, CTV News’ Eric Longley donned the “RA Experience Suit” and wandered around Ottawa’s Byward Market, getting a glimpse into what it’s like to live with rheumatoid arthritis. Click on “Suiting up for a Cause” to watch him attempt simple actions that most people not living with arthritis take for granted.

And just yesterday, the Richmond Review published an editorial article entitled, “Great work being done at arthritis research centre” about the Government of British Columbia’s donation of $3 million dollars to ARC to help further developments in arthritis prevention, diagnosis, and treatment. For more information on the government’s announcement, please click here.

the news

Image courtesy of hywards at FreeDigitalPhotos.net

The “My Wait Time Story” Campaign

Three chairs in a waiting roomHow has a long wait for healthcare affected you? The Wait Time Alliance (WTA) is asking Canadians to create a video and share their wait time story. On September 23, the WTA is taking the cause to Parliament Hill and wants our political leaders to understand the effects unnecessary waiting for medical care has on Canadians by hearing their stories directly.

“We look forward to bringing the voice of patients to the forefront to show our elected representatives that addressing wait times remains a critical factor if we want to improve our health system,” said Dr. Chris Simpson, Chair, Wait Time Alliance.

2014 marks the end of the 10-year Health Accord in which federal, provincial and territorial governments committed to reducing wait times in five initial areas. But medical wait times remain as much of an issue today as they were in 2004. The expiry of the Accord brings an opportunity to re-visit the federal government’s crucial role in healthcare.

Video submissions must:

  • Be no longer than 3 minutes in length.
  • Demonstrate the challenges faced by you and your loved ones navigating the system in a respectful manner.
  • Offer any suggestions you might have as to how to improve the process to benefit those patients that follow in your path.
  • Protect your privacy and the privacy of others. Give only your first name and province, nothing more. Do not relay other patient stories.
  • Not infringe upon or violate any laws or third party rights, including, but not limited to, copyright, patent, and trademark.

Click here for the video submission page.

 

The Wait Time Alliance logo

About the Wait Time Alliance:

The Wait Time Alliance (WTA) is a partnership composed of the Canadian Anesthesiologists’ Society, the Canadian Association of Emergency Physicians, the Canadian Association of Gastroenterology, the Canadian Association of General Surgeons, the Canadian Association of Nuclear Medicine, the Canadian Association of Paediatric Surgeons, the Canadian Association of Radiation Oncology, the Canadian Association of Radiologists, the Canadian Cardiovascular Society, the Canadian Geriatrics Society, the Canadian Medical Association, the Canadian Ophthalmological Society, the Canadian Orthopaedic Association, the Canadian Psychiatric Association, the Canadian Rheumatology Association, the Canadian Society of Plastic Surgeons, the College of Family Physicians of Canada, and the Society of Obstetricians and Gynaecologists of Canada.

Call for patient organization input

Stickman with megaphone calling for patient organization inputCall for patient organization input on certolizumab pegol (Cimzia®) for psoriatic arthritis

Do you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (PsA). Certolizumab pegol is indicated for use in combination with methotrexate for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs). Continue reading